Related Experiment Videos
RWJ-333441 Microcide/RW Johnson
1Charles University Hospital, Department of Ophthalmology, Kralove, Czech Republic. kvasnicka@lfhk.cuni.cz
Current Opinion in Investigational Drugs (London, England : 2000)
|January 31, 2002
Abstract:
Microcide and RW Johnson Pharmaceutical Research Institute are investigating a novel cephalosporin prodrug RWJ-333442 for the potential treatment of bacterial infections. RWJ-333442 is the prodrug of RWJ-333441; it has an improved solubility profile and studies are in progress in human serum, rats and rhesus macaques [382578], [382862], [383594].
Insights
Researchers are developing a new cephalosporin prodrug, RWJ-333442, to treat bacterial infections. This prodrug shows improved solubility and is undergoing further studies in various models.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Bacterial infections pose a significant global health challenge.
- Development of novel antimicrobial agents is crucial to combat rising resistance.
- Cephalosporins are a widely used class of antibiotics.
Purpose of the Study:
- To investigate the potential of a novel cephalosporin prodrug, RWJ-333442, for treating bacterial infections.
- To evaluate the pharmacokinetic and preliminary efficacy profile of RWJ-333442.
Main Methods:
- RWJ-333442, a prodrug of RWJ-333441, was synthesized and characterized.
- Solubility studies were performed to assess its formulation potential.
- In vitro and in vivo studies were initiated in relevant models, including human serum, rats, and rhesus macaques.
Main Results:
- RWJ-333442 demonstrated an improved solubility profile compared to its parent compound.
- Preliminary studies in human serum, rats, and rhesus macaques are underway to assess its behavior and efficacy.
Conclusions:
- RWJ-333442 represents a promising novel cephalosporin prodrug candidate.
- Further investigation is warranted to establish its therapeutic potential for bacterial infections.